10-Q: BioSig Technologies Reports Q1 2025 Results, Regains Nasdaq Compliance

BioSig Technologies reports a net loss for Q1 2025 but regains compliance with Nasdaq listing requirements.

Summary

• BioSig Technologies, Inc. reported its financial results for the first quarter of 2025.
• The company had minimal revenue of $0 for the three months ended March 31, 2025, compared to $14 thousand in the same period of 2024.
• The net loss attributable to common shareholders was $2.814 million, compared to a net loss of $3.537 million for the three months ended March 31, 2024.
• Research and development expenses decreased significantly to $6 thousand from $238 thousand year-over-year.
• General and administrative expenses increased slightly to $2.957 million from $2.882 million.
• The company regained compliance with Nasdaq listing requirements after maintaining a minimum closing bid price of $1.00 for ten consecutive business days.
• As of March 31, 2025, BioSig had cash of $3.7 million and a working capital surplus of $2.31 million.
• The company has an accumulated deficit of $258.16 million as of March 31, 2025.
• BioSig is pursuing a merger transaction with Streamex Exchange Corporation, which could result in current Streamex stockholders owning approximately 75% of the outstanding common stock of BioSig after conversion of preferred stock.
• The company identified material weaknesses in its internal control over financial reporting related to stock-based compensation, review processes, and segregation of duties.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company regained Nasdaq compliance and reduced R&D expenses, it still reported a net loss and identified material weaknesses in internal controls. The proposed merger adds uncertainty.

Positives

• BioSig Technologies regained compliance with Nasdaq listing requirements.
• Research and development expenses decreased significantly, indicating a potential shift towards commercialization.
• The company has a working capital surplus of $2.31 million.
• The company is pursuing a merger with Streamex Exchange Corporation, which could provide new opportunities.
• Net loss attributable to common shareholders decreased from $3.537 million to $2.814 million.

Negatives

• BioSig Technologies reported a net loss attributable to common shareholders of $2.814 million for Q1 2025.
• The company had minimal revenue of $0 for the three months ended March 31, 2025.
• The company has an accumulated deficit of $258.16 million as of March 31, 2025.
• BioSig identified material weaknesses in its internal control over financial reporting.
• The proposed merger with Streamex Exchange Corporation could result in significant dilution for existing BioSig shareholders.

Risks

• The company's ability to continue as a going concern is subject to its ability to obtain necessary funding from outside sources.
• The proposed merger with Streamex Exchange Corporation is subject to completion of due diligence and definitive documentation, as well as regulatory and listing approvals.
• The company identified material weaknesses in its internal control over financial reporting, which could impact its ability to accurately report financial results.
• The company may be subject to legal proceedings and claims, which could have a material adverse effect on its financial position.
• The company's Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of $1 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%.

Future Outlook

The company anticipates that its results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of its research and development and commercialization efforts, the timing and outcome of future regulatory submissions and uncertainty around the current pandemic.

Industry Context

The medical device industry is highly competitive, with companies constantly innovating and developing new technologies. BioSig's focus on improving the specificity of PFA treatment and improving clinical outcomes aligns with the industry's trend towards more precise and effective therapies.

Comparison to Industry Standards

• It is difficult to compare BioSig's results directly to industry standards due to its early commercialization stage and unique technology platform.
• Comparable companies in the medical device space include Medtronic, Abbott, and Boston Scientific, but these companies have a much broader product portfolio and established revenue streams.
• BioSig's success will depend on its ability to successfully commercialize its PURE EP system and demonstrate its clinical and economic value to healthcare providers.
• The proposed merger with Streamex could provide BioSig with access to new markets and technologies, but the success of the merger will depend on the integration of the two companies and the realization of synergies.

Management Changes

Legal Proceedings

• On February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from alleged unlawful actions taken by the Company and its board of directors.
• On March 24, 2025, the Company entered into a settlement agreement with the claimant and accrued $493,800 as of March 31, 2025 and December 31, 2024.

Related Party Transactions

• Accounts payable and accrued expenses include due to related parties comprised primarily director fees and travel reimbursements.
• In January 2025 the Company issued 25,000 shares of its common stock to Mr. Groenewald, the Interim Chief Financial Officer, with an aggregate grant date fair value of $35,000.
• In March 2025 the Company issued 212,500 shares of its common stock to Mr. Amato, the Chief Executive Officer, for vested restricted stock units.

Stakeholder Impact

• Shareholders may experience dilution due to the proposed merger with Streamex and potential future equity offerings.
• Employees may be affected by the company's cost-saving measures and potential restructuring.
• Customers may benefit from the company's continued development and commercialization of the PURE EP System.
• Creditors may be at risk if the company is unable to obtain necessary funding and continue as a going concern.

Next Steps

• The company intends to implement remediation plans in 2025 to address the material weaknesses in its internal control over financial reporting.
• The company will continue to pursue the proposed merger transaction with Streamex Exchange Corporation, subject to due diligence and regulatory approvals.
• The company will continue the commercialization of the PURE EP System and other applications of its core technology.
• The company will continue to raise capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships.

Key Dates

Keywords

BioSig Technologies, Nasdaq, financial results, Q1 2025, merger, Streamex, PURE EP, compliance, internal control, equity financing